Literature DB >> 2544523

Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis.

W A Pettinger1, H C Lee, J Reisch, H C Mitchell.   

Abstract

Seventy-nine hypertensive nephrosclerosis patients entered a prospective randomized single-blind study to 1) establish the pattern of decay of renal function in this population and the variability therein and 2) to determine if strict diastolic blood pressure (DBP) control (less than or equal to 80 mm Hg) is more effective than conventional levels (90-95 mm Hg) in conserving renal function. Because of unexpected significant improvement in renal function in patients from both groups, which changed the perspectives on the course of this disease as described herein, this report is being published before completion of the trial. The selection criteria were 1) serum creatinine concentration of 1.6-7.0 mg/dl, 2) glomerular filtration rate of less than 70 ml/min/1.73 m2, and 3) absence of diseases (other than hypertension) known to destroy renal function. Renal function was assessed by glomerular filtration rate [( 125I]iothalamate clearance) and serum creatinine concentration. Before randomization, DBP was aggressively treated to reduce it to less than 80 mm Hg. Twenty-two subjects (14 in the strict DBP control group and eight in the conventional DBP control group) have been enrolled in the study for 36 months. In contrast to results from previous studies in humans and rats, renal function improved in both patient groups. Thus, irrevocable progression of renal damage after onset of renal failure from high blood pressure does not necessarily occur, and in fact, long-term improvement of renal function resulted from the effects of the study itself.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2544523     DOI: 10.1161/01.hyp.13.6.766

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

Review 1.  Hypertension's 3 Dilemmas and 3 Solutions: Pharmacology of the Kidney in Hypertension.

Authors:  William A Pettinger
Journal:  J Cardiovasc Pharmacol       Date:  2017-03       Impact factor: 3.105

Review 2.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 3.  ACE inhibitors in non-diabetic renal disease.

Authors:  R J Fluck; A E Raine
Journal:  Br Heart J       Date:  1994-09

Review 4.  Do glomerular hemodynamic adaptations influence the progression of human renal disease?

Authors:  A S Woolf; L G Fine
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

5.  Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients. A randomized controlled study versus placebo.

Authors:  G Licata; R Scaglione; A Ganguzza; G Parrinello; R Costa; G Merlino; S Corrao; P Amato
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  ACE inhibitors in elderly patients with hypertension. Special considerations.

Authors:  M Ravid; D Ravid
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

Review 7.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

8.  Short-term hypertension management in community is associated with long-term risk of stroke and total death in China: A community controlled trial.

Authors:  Zengwu Wang; Guang Hao; Xin Wang; Wen Wang; Weiwei Chen; Manlu Zhu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

9.  Estimated glomerular filtration rate reversal by blood pressure lowering in chronic kidney disease: Japan Multicenter Investigation for Cardiovascular DiseaseB CKD study.

Authors:  Yoshiki Yui; Kazuhisa Kodama; Atsushi Hirayama; Saichi Hosoda; Chuichi Kawai
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-12-14       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.